NASDAQ:IMGN - ImmunoGen Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $10.75
  • Forecasted Upside: 94.75 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$5.52
▲ +0.22 (4.15%)
1 month | 3 months | 12 months
Get New ImmunoGen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IMGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IMGN

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$10.75
▲ +94.75% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for ImmunoGen in the last 3 months. The average price target is $10.75, with a high forecast of $14.00 and a low forecast of $6.00. The average price target represents a 94.75% upside from the last price of $5.52.
Buy
The current consensus among 7 contributing investment analysts is to buy stock in ImmunoGen. This rating has held steady since February 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 0 sell ratings
6/7/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 0 sell ratings
9/5/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 0 sell ratings
12/4/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/3/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/1/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/30/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/29/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/28/2020

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/9/2020HC WainwrightReiterated RatingBuyMedium
i
Rating by S. Ramakanth at HC Wainwright
11/6/2020SVB LeerinkBoost Price TargetMarket Perform$5.00 ➝ $6.00Low
i
10/26/2020HC WainwrightReiterated RatingBuy$11.00Low
i
10/20/2020Canaccord GenuityReiterated RatingBuy$12.00High
i
10/6/2020SVB LeerinkBoost Price TargetMarket Perform$4.00 ➝ $5.00Medium
i
10/2/2020GuggenheimUpgradeNeutral ➝ Buy$14.00High
i
9/29/2020JPMorgan Chase & Co.Initiated CoverageNeutralLow
i
9/18/2020William BlairReiterated RatingBuyHigh
i
8/3/2020Canaccord GenuityReiterated RatingBuyLow
i
6/1/2020HC WainwrightReiterated RatingBuy$9.00Low
i
Rating by Debjit Chattopadhyay at HC Wainwright
5/14/2020Canaccord GenuityReiterated RatingBuy$12.00High
i
5/4/2020Canaccord GenuityReiterated RatingBuy$12.00High
i
12/17/2019HC WainwrightReiterated RatingBuy$5.00 ➝ $9.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
12/10/2019HC WainwrightReiterated RatingBuy$5.00Low
i
Rating by Debjit Chattopadhyay at HC Wainwright
12/10/2019CowenReiterated RatingBuyLow
i
Rating by Boris Peaker at Cowen Inc
9/30/2019CowenReiterated RatingBuyHigh
i
Rating by Boris Peaker at Cowen Inc
9/24/2019SVB LeerinkReiterated RatingHoldMedium
i
Rating by Jonathan Chang at SVB Leerink LLC
8/13/2019HC WainwrightReiterated RatingBuy ➝ Buy$4.00 ➝ $5.00Low
i
Rating by Debjit Chattopadhyay at HC Wainwright
6/28/2019HC WainwrightSet Price TargetBuy$4.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
6/27/2019CowenReiterated RatingBuyHigh
i
6/2/2019CowenReiterated RatingBuyMedium
i
5/16/2019HC WainwrightLower Price TargetBuy$7.00 ➝ $4.00High
i
Rating by D. Chattopadhyay at HC Wainwright
5/15/2019GuggenheimDowngradeBuy ➝ NeutralHigh
i
5/6/2019HC WainwrightUpgradeNeutral ➝ Buy$7.00High
i
Rating by D. Chattopadhyay at HC Wainwright
5/6/2019CowenUpgradeMarket Perform ➝ Outperform$2.94High
i
3/19/2019JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightHigh
i
3/5/2019Morgan StanleyUpgradeUnderweight ➝ Equal Weight$2.68Low
i
3/4/2019SVB LeerinkDowngradeOutperform ➝ Market PerformHigh
i
Rating by J. Chang at SVB Leerink LLC
3/4/2019HC WainwrightDowngradeBuy ➝ Neutral$18.00 ➝ $3.50Medium
i
Rating by Debjit Chattopadhyay at HC Wainwright
3/1/2019SVB LeerinkDowngradeOutperform ➝ Market PerformMedium
i
3/1/2019CowenReiterated RatingHoldHigh
i
3/1/2019Jefferies Financial GroupDowngradeBuy ➝ HoldHigh
i
3/1/2019Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$13.00 ➝ $2.50High
i
Rating by Joseph Catanzaro at Piper Jaffray Companies
1/3/2019HC WainwrightReiterated RatingBuyMedium
i
Rating by Debjit Chattopadhyay at HC Wainwright
12/3/2018HC WainwrightSet Price TargetBuy$18.00Low
i
Rating by Debjit Chattopadhyay at HC Wainwright
12/2/2018Piper Jaffray CompaniesSet Price TargetBuy$14.00Medium
i
Rating by Joseph Catanzaro at Piper Jaffray Companies
11/6/2018HC WainwrightSet Price TargetBuy$18.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
10/31/2018HC WainwrightSet Price TargetBuy$18.00Medium
i
Rating by Debjit Chattopadhyay at HC Wainwright
10/22/2018William BlairReiterated RatingOutperformHigh
i
10/22/2018HC WainwrightSet Price TargetBuy$18.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
10/8/2018HC WainwrightSet Price TargetBuy$18.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
9/17/2018GuggenheimInitiated CoverageBuyLow
i
9/6/2018Piper Jaffray CompaniesInitiated CoverageOverweight ➝ OverweightLow
i
7/30/2018HC WainwrightReiterated RatingBuy$18.00Medium
i
Rating by Debjit Chattopadhyay at HC Wainwright
7/27/2018CowenReiterated RatingHoldHigh
i
6/13/2018HC WainwrightSet Price TargetBuy$18.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
6/5/2018HC WainwrightSet Price TargetBuy$18.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
5/17/2018CowenReiterated RatingHoldMedium
i
5/17/2018HC WainwrightSet Price TargetBuy$18.00Medium
i
Rating by Debjit Chattopadhyay at HC Wainwright
5/7/2018HC WainwrightSet Price TargetBuy$18.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
4/27/2018Canaccord GenuityReiterated RatingBuy$20.00Low
i
4/25/2018HC WainwrightSet Price TargetBuy$18.00Low
i
Rating by Debjit Chattopadhyay at HC Wainwright
4/10/2018HC WainwrightSet Price TargetBuy$18.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
4/8/2018Cantor FitzgeraldSet Price TargetHold$5.00Low
i
Rating by Mara Goldstein at Cantor Fitzgerald
3/26/2018SVB LeerinkReiterated RatingOutperformMedium
i
Rating by J. Chang at SVB Leerink LLC
3/26/2018HC WainwrightSet Price TargetBuy$18.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
3/25/2018Cantor FitzgeraldSet Price TargetHold$5.00High
i
Rating by Mara Goldstein at Cantor Fitzgerald
3/21/2018Royal Bank of CanadaBoost Price TargetOutperform$16.00Low
i
3/12/2018HC WainwrightSet Price TargetBuy$18.00Medium
i
Rating by Debjit Chattopadhyay at HC Wainwright
2/12/2018HC WainwrightSet Price TargetBuy$18.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
2/8/2018Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$12.00Medium
i
1/31/2018HC WainwrightInitiated CoverageBuy ➝ BuyHigh
i
Rating by D. Chattopadhyay at HC Wainwright
11/3/2017Cantor FitzgeraldReiterated RatingHold$5.00N/A
i
Rating by Mara Goldstein at Cantor Fitzgerald
10/12/2017Jefferies Financial GroupReiterated RatingBuy$9.00N/A
i
9/25/2017Cantor FitzgeraldReiterated RatingHold$5.00Medium
i
Rating by Mara Goldstein at Cantor Fitzgerald
8/30/2017Canaccord GenuityReiterated RatingBuy$8.00 ➝ $10.00Medium
i
Rating by John Newman at Canaccord Genuity
8/29/2017CowenReiterated RatingHoldHigh
i
Rating by Boris Peaker at Cowen Inc
8/29/2017SVB LeerinkReiterated RatingOutperform ➝ BuyHigh
i
Rating by M. Schmidt at SVB Leerink LLC
8/29/2017Cantor FitzgeraldReiterated RatingHoldHigh
i
Rating by Mara Goldstein at Cantor Fitzgerald
8/7/2017Jefferies Financial GroupReiterated RatingBuy$9.00Medium
i
7/31/2017Canaccord GenuitySet Price TargetBuy$8.00High
i
Rating by John Newman at Canaccord Genuity
7/28/2017Cantor FitzgeraldSet Price TargetHold$5.00High
i
Rating by Mara Goldstein at Cantor Fitzgerald
7/6/2017Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$5.00 ➝ $12.00High
i
Rating by Matthew Eckler at Royal Bank of Canada
6/28/2017Jefferies Financial GroupReiterated RatingBuy$6.00High
i
6/26/2017Royal Bank of CanadaSet Price TargetHold$5.00N/A
i
Rating by Matthew Eckler at Royal Bank of Canada
6/26/2017William BlairReiterated RatingOutperformHigh
i
Rating by A. Hsieh at William Blair
6/19/2017SVB LeerinkReiterated RatingOutperform$8.00 ➝ $11.00High
i
Rating by M. Schmidt at SVB Leerink LLC
6/4/2017Cantor FitzgeraldSet Price TargetHold$5.00Medium
i
Rating by Mara Goldstein at Cantor Fitzgerald
5/24/2017Cantor FitzgeraldReiterated RatingHold$5.00Low
i
5/19/2017Canaccord GenuitySet Price TargetBuy$6.00Low
i
Rating by John Newman at Canaccord Genuity
5/18/2017Jefferies Financial GroupReiterated RatingBuy$6.00High
i
5/8/2017Cantor FitzgeraldReiterated RatingHold$5.00High
i
5/6/2017Canaccord GenuitySet Price TargetBuy$6.00High
i
Rating by John Newman at Canaccord Genuity
5/6/2017CowenReiterated RatingHoldHigh
i
Rating by Boris Peaker at Cowen Inc
5/6/2017Royal Bank of CanadaSet Price TargetHold$5.00High
i
Rating by Matthew Eckler at Royal Bank of Canada
4/19/2017SVB LeerinkUpgradeMarket Perform ➝ Outperform$3.53 ➝ $3.90High
i
Rating by M. Schmidt at SVB Leerink LLC
4/12/2017Jefferies Financial GroupReiterated RatingBuy$6.00Low
i
3/13/2017CowenReiterated RatingHoldMedium
i
3/1/2017Morgan StanleyLower Price TargetUnderweight$2.50 ➝ $1.30N/A
i
2/18/2017Canaccord GenuitySet Price TargetBuy$6.00N/A
i
Rating by John Newman at Canaccord Genuity
2/18/2017Royal Bank of CanadaSet Price TargetHold$3.00N/A
i
Rating by Simos Simeonidis at Royal Bank of Canada
1/3/2017Royal Bank of CanadaReiterated RatingHold$2.00N/A
i
10/30/2016Cantor FitzgeraldSet Price TargetHold$5.00N/A
i
Rating by Mara Goldstein at Cantor Fitzgerald
10/28/2016Canaccord GenuitySet Price TargetBuy$6.00N/A
i
Rating by John Newman at Canaccord Genuity
8/5/2016Jefferies Financial GroupReiterated RatingBuy$13.00 ➝ $6.00N/A
i
8/5/2016JPMorgan Chase & Co.Set Price TargetHold$9.00 ➝ $5.00N/A
i
Rating by Jessica Fye at JPMorgan Chase & Co.
6/8/2016Cantor FitzgeraldReiterated RatingHoldN/A
i
Rating by Mara Goldstein at Cantor Fitzgerald
6/6/2016CowenReiterated RatingHoldN/A
i
Rating by Boris Peaker at Cowen Inc
5/19/2016Royal Bank of CanadaReiterated RatingSector Perform$7.00N/A
i
Rating by Simos Simeonidis at Royal Bank of Canada
5/5/2016Morgan StanleyReiterated RatingUnderweight$9.00 ➝ $5.00N/A
i
5/2/2016SVB LeerinkBoost Price TargetMarket Perform$8.00 ➝ $11.00N/A
i
4/30/2016Canaccord GenuityReiterated RatingBuyN/A
i
Rating by John Newman at Canaccord Genuity
4/29/2016CowenReiterated RatingHold$8.50N/A
i
Rating by Boris Peaker at Cowen Inc
4/29/2016Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$18.00 ➝ $7.00N/A
i
4/17/2016CowenReiterated RatingHoldN/A
i
Rating by Boris Peaker at Cowen Inc
2/4/2016Canaccord GenuityReiterated RatingBuy$20.00N/A
i
Rating by John Newman at Canaccord Genuity
2/1/2016Royal Bank of CanadaLower Price TargetOutperform$19.00 ➝ $18.00N/A
i
1/31/2016William BlairReiterated RatingOutperformN/A
i
1/29/2016Canaccord GenuityReiterated RatingBuyN/A
i
Rating by Benji Star at Canaccord Genuity
12/3/2015Jefferies Financial GroupReiterated RatingHold$8.00N/A
i
Rating by Biren Amin at Jefferies Financial Group Inc.
(Data available from 11/29/2015 forward)
ImmunoGen logo
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. Its preclinical program include IMGC936, an investigational ADC in co-development with MacroGenics, Inc. ImmunoGen, Inc. has collaborations with Roche; Amgen/Oxford BioTherapeutics; sanofi-aventis U. S. LLC; Biotest AG; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Fusion Pharmaceuticals Inc.; Debiopharm International SA; Jazz Pharmaceuticals Ireland Limited; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $5.52
$5.34
$5.56

50 Day Range

MA: $5.60
$4.30
$6.21

52 Week Range

Now: $5.52
$1.95
$7.07

Volume

952,647 shs

Average Volume

2,782,193 shs

Market Capitalization

$1.04 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.79